What do we know about memory B cells in primary Sjogren's syndrome?

被引:24
|
作者
Hansen, Arne [1 ,2 ]
Daridon, Capucine [3 ]
Doerner, Thomas [3 ]
机构
[1] Akad Lehrkrankenhaus Charite, Pk Klink Weissensee, Dept Med, D-13086 Berlin, Germany
[2] Charite, Outpatients Dept Med, Berlin, Germany
[3] Charite, Dept Rheumatol & Clin Immunol, Berlin, Germany
关键词
Primary Sjogrens syndrome; Autoimmunity; Memory B cells; Lymphoma; Rituximab; DEPRESSED PERCENTAGE; AUTOIMMUNE-DISEASES; SALIVARY-GLANDS; BLOOD; EXPRESSION; RITUXIMAB; CD27; HETEROGENEITY; CORRELATE; LYMPHOMA;
D O I
10.1016/j.autrev.2010.05.005
中图分类号
R392 [医学免疫学]; Q939.91 [免疫学];
学科分类号
100102 ;
摘要
Abnormalities of memory B cells seem to be closely involved in the pathogenesis of primary Sjogrens Syndrome (pSS) and its malignant complication, B cell lymphoma. Recent studies on B cells in pSS add to our understanding of the distinct memory B cell subsets in pSS. Reduction of peripheral memory CD27(+) B cells, most strikingly of the CD27(+) IgM(+) subset, may indicate a lack of appropriate censoring mechanisms and Incomplete differentiation processes within the ectopic lymphoid tissues in pSS. This ectopically formed lymphoid tissue might protect autoreactive memory B cells from deletion by physiological check-points and, thereby, may contribute to the perpetuation of the disease as well as to an enhanced lymphoma risk. Thus, B cells may be potential targets of direct or indirect treatment in pSS (C) 2010 Elsevier B V All rights reserved
引用
收藏
页码:600 / 603
页数:4
相关论文
共 50 条
  • [1] Disease mechanisms in Sjogren's syndrome: What do we know?
    Jonsson, Roland
    [J]. SCANDINAVIAN JOURNAL OF IMMUNOLOGY, 2022, 95 (03)
  • [2] What do we know about Tietze's syndrome?
    Rokicki, Wojciech
    Rokicki, Marek
    Rydel, Mateusz
    [J]. KARDIOCHIRURGIA I TORAKOCHIRURGIA POLSKA, 2018, 15 (03): : 180 - 182
  • [3] What do we know and what do we know about evolution?
    Vlchev, Boris
    [J]. SPISANIE NA B LGARSKOTO GEOLOGICHESKO DRUZHESTOV-REVIEW OF THE BULGARIAN GEOLOGICAL SOCIETY, 2020, 81 : 101 - 101
  • [4] Pathogenesis of Sjogren's syndrome: What we know and what we should learn
    Tzioufas, Athanasios G.
    Kapsogeorgou, Efstathia K.
    Moutsopoulos, Haralampos M.
    [J]. JOURNAL OF AUTOIMMUNITY, 2012, 39 (1-2) : 4 - 8
  • [5] Primary pleuropulmonary sarcoma: what do we know about it?
    Levra, Matteo Giaj
    Novello, Silvia
    Le Cesne, Axel
    [J]. LUNG CANCER MANAGEMENT, 2014, 3 (02) : 119 - 121
  • [6] What we know and what we do not know about DMN
    Figl, Kathrin
    Mendling, Jan
    Tokdemir, Gul
    Vanthienen, Jan
    [J]. ENTERPRISE MODELLING AND INFORMATION SYSTEMS ARCHITECTURES-AN INTERNATIONAL JOURNAL, 2018, 13
  • [7] What do we know and need to know about transforming primary care?
    Solberg, Leif I.
    [J]. FAMILY PRACTICE, 2017, 34 (04) : 371 - 372
  • [8] What about glucocorticoids in primary Sjogren's syndrome?
    Priori, R.
    Mastromanno, L.
    Izzo, R.
    [J]. CLINICAL AND EXPERIMENTAL RHEUMATOLOGY, 2020, 38 (04) : S237 - S244
  • [9] What we know and mostly do not know about bronchiolitis obliterans syndrome
    Martin, P. J.
    Chien, J. W.
    [J]. BONE MARROW TRANSPLANTATION, 2012, 47 (01) : 1 - 4
  • [10] What we know and mostly do not know about bronchiolitis obliterans syndrome
    P J Martin
    J W Chien
    [J]. Bone Marrow Transplantation, 2012, 47 : 1 - 4